pet -flt monitoring of therapy response in head and neck cancer
TRANSCRIPT
![Page 1: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/1.jpg)
Juan Carlos Mazabuel Quintero
R3 Radioterapia
![Page 2: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/2.jpg)
INDICE
JUSTIFICACIÓN
GENERALIDADES
ESTUDIOS
CONCLUSIONES
DISCUSION
BIBLIOGRAFIA
![Page 3: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/3.jpg)
GENERALIDADES Tumores de C y C representan el 5-7% de los TM.
Tasa de incidencia estandarizada de 20,1 en hombres y 3,1 en mujeres x 100.000 Hab.
Según la IARC anualmente se diagnostican 634.760 casos y fallecen 356.705 pacientes .
El 95% son de tipo Escamoso . 1/3 se presentan es estadios precoces (T1-T2 ) y 2/3 en estadios avanzados (T3-T4 , N1-N3 ) .
Según CNE para 2012 en España estos tumores causaron 5.397 defunciones = 4.743 h. y 654 m.
Según EUROCARE la supervivencia estimada a 5 años es del 49,5% .
![Page 4: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/4.jpg)
![Page 5: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/5.jpg)
![Page 6: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/6.jpg)
METABOLISMO DE FDG
![Page 7: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/7.jpg)
![Page 8: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/8.jpg)
![Page 9: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/9.jpg)
![Page 10: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/10.jpg)
![Page 11: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/11.jpg)
![Page 12: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/12.jpg)
![Page 13: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/13.jpg)
![Page 14: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/14.jpg)
![Page 15: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/15.jpg)
![Page 16: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/16.jpg)
![Page 17: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/17.jpg)
FALSE – POSITIVE PET/CT
![Page 18: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/18.jpg)
TRUE – NEGATIVE PET / CT
![Page 19: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/19.jpg)
TRUE – POSITIVE PET/CT
![Page 20: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/20.jpg)
Suggested algorithm for management of HNSCC
![Page 21: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/21.jpg)
RADIOFARMACOS EN ESTUDIO
![Page 22: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/22.jpg)
![Page 23: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/23.jpg)
![Page 24: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/24.jpg)
![Page 25: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/25.jpg)
![Page 26: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/26.jpg)
![Page 27: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/27.jpg)
![Page 28: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/28.jpg)
![Page 29: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/29.jpg)
CONCLUSIONES El PET - CT /FDG es muy útil para detectar enfermedad residual o recurrente en
cáncer de cabeza y cuello con S : 94% y E: 82% .
Un PET -CT /FDG Negativo es altamente predictivo de ausencia de enfermedad , con un VPN : 95% .
Con un PET-CT /FDG negativo puede potencialmente obviarse una disección planeada de cuello y/o una endoscopia de vigilancia .
La sensibilidad del PET-CT / FDG es baja en las 10 semanas pos-tratamiento .
En cáncer de C y C cambios tempranos en la captación del PET-CT / FLT durante la QT-RT . Es un fuerte predictor de resultado a largo tiempo.
El PET-CT / FLT puede ayudar a la modificicación de tratamientos QT-RT durante la fase temprana de evaluación.
![Page 30: PET -FLT Monitoring of therapy response in Head and Neck Cancer](https://reader036.vdocuments.mx/reader036/viewer/2022062313/558ba953d8b42a38568b4569/html5/thumbnails/30.jpg)